Anthera Pharmaceuticals, Inc. (ANTH) Upgraded at Zacks Investment Research
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage currently has a $2.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 11.73% from the company’s current price.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
Other research analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. Jefferies Group LLC reiterated a “hold” rating and set a $1.75 price target (down previously from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th. Finally, ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $5.11.
Anthera Pharmaceuticals (NASDAQ ANTH) traded up 4.07% on Tuesday, reaching $1.79. The company’s stock had a trading volume of 541,827 shares. The firm’s market capitalization is $19.52 million. Anthera Pharmaceuticals has a 52-week low of $1.20 and a 52-week high of $3.22. The firm has a 50-day moving average price of $1.45 and a 200 day moving average price of $1.38.
Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $1.12. Equities analysts anticipate that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current fiscal year.
WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/10/anthera-pharmaceuticals-inc-anth-upgraded-at-zacks-investment-research.html.
Hedge funds and other institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its stake in Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 335,595 shares in the last quarter. UBS Group AG grew its stake in Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 33,901 shares in the last quarter. Finally, Sabby Management LLC grew its stake in Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after purchasing an additional 1,665,655 shares in the last quarter. Hedge funds and other institutional investors own 27.26% of the company’s stock.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.